Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ImageneBio Inc (IMA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.17+1.59%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for IMA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advance late-phase development readiness for atopic dermatitis treatment | The company is preparing late-stage development for atopic dermatitis treatment. | Intact | Failure to reach late-phase development readiness for atopic dermatitis by end of 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
IMA is a speculative growth business, not a proven earnings compounder, because it is loss-making and depends on clinical development. The long-term thesis is intact, with recent financial performance in the top half of its industry, but management has been volatile and overall risk is high.
The valuation is at a durable premium to peers, while the model shows only a small expectations gap and has low confidence. The evidence labels the premium justified and shows no fragility gates, but it does not establish that the valuation is cheap or that expectations leave much room for disappointment.
Near term, clinical spending is likely to remain elevated as IMA advances IMG-007; recent cash increased to $136.2 million, which management expects to support operations into Q1 2028. Cost control is mixed, with lower general and administrative expenses but modestly higher research and development costs. The next report carries meaningful execution risk, and a guidance cut or further weakening in jobs data could add pressure to the business outlook.
The multi-year view hinges on progress in the atopic dermatitis trial, with topline data expected in Q4 2027, and on the planned alopecia areata trial, with initial data expected in 2028. Cash runway and expense discipline also matter while results remain pending. Near term, guidance and the broader Healthcare sector backdrop are swing factors, including whether sector bellwethers continue to report strong results and raise guidance.
For the next 1 to 3 years, IMA remains an intact but high-risk clinical development thesis, supported by cash runway and sector momentum but constrained by losses, management volatility, and pending trial evidence. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in ImageneBio Inc's published investment case. The stated target is Cash runway sufficient to fund operations through end of 2027. |
| Intact |
| Cash runway falls below 12 months before reaching key milestones |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Expand IMG-007 into additional indications including alopecia areata | ImageneBio is advancing key drug candidates like IMG-007 into new uses including alopecia areata. | Intact | No meaningful progress or trial starts for IMG-007 in new indications by end of 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain stable and effective management team | A supporting condition in ImageneBio Inc's published investment case. The stated target is No further key executive departures through 2026. | Under Pressure | Additional senior management resignations or board instability in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.07 → $-3.48 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.07 | $144,707 | 2 / 3 |
| 2026-07-25 | $-3.07 | $144,707 | 2 / 3 |
| 2026-07-26 | $-3.98 | $0 | 2 / 3 |
| 2026-07-27 | $-3.07 | $144,707 | 2 / 3 |
| 2026-07-28 | $-3.07 | $144,707 | 2 / 3 |
| 2026-07-29 | $-3.98 | $0 | 2 / 3 |
| 2026-07-30 | $-3.98 | $0 | 2 / 3 |
| 2026-07-31 | $-3.98 | $0 | 2 / 3 |
| 2026-08-01 | $-3.07 | $144,707 | 2 / 3 |
| 2026-08-02 | $-3.98 | $0 | 2 / 3 |
| 2026-08-03 | $-3.98 | $0 | 2 / 3 |
| 2026-08-04 | $-3.98 | $0 | 2 / 3 |
| 2026-08-05 | $-3.98 | $0 | 2 / 3 |
| 2026-08-06 | $-3.98 | $0 | 2 / 3 |
| 2026-08-07 | $-2.78 | $144,707 | 2 / 3 |
| 2026-08-08 | $-3.73 | $0 | 2 / 3 |
| 2026-08-09 | $-3.73 | $0 | 2 / 3 |
| 2026-08-10 | $-2.78 | $144,707 | 2 / 3 |
| 2026-08-12 | $-2.78 | $144,707 | 2 / 3 |
| 2026-08-13 | $-2.78 | $144,707 | 2 / 3 |
| 2026-08-14 | $-2.78 | $144,707 | 2 / 3 |
| 2026-08-15 | $-2.78 | $144,707 | 2 / 3 |
| 2026-08-16 | $-2.78 | $144,707 | 2 / 3 |
| 2026-08-17 | $-2.78 | $144,707 | 2 / 3 |
| 2026-08-18 | $-2.78 | $144,707 | 2 / 3 |
| 2026-08-19 | $-2.78 | $144,707 | 2 / 3 |
| 2026-08-20 | $-2.78 | $144,707 | 2 / 3 |
| 2026-08-21 | $-2.78 | $144,707 | 2 / 3 |
| 2026-08-22 | $-2.78 | $144,707 | 2 / 3 |
| 2026-08-23 | $-3.45 | $144,707 | 2 / 4 |
| 2026-08-24 | $-3.45 | $144,707 | 3 / 4 |
| 2026-08-25 | $-3.45 | $144,707 | 3 / 4 |
| 2026-08-26 | $-3.45 | $144,707 | 3 / 4 |
| 2026-08-27 | $-3.45 | $144,707 | 3 / 4 |
| 2026-08-28 | $-3.45 | $144,707 | 3 / 4 |
| 2026-08-29 | $-3.45 | $144,707 | 3 / 4 |
| 2026-08-30 | $-3.45 | $144,707 | 3 / 4 |
| 2026-08-31 | $-3.45 | $144,707 | 3 / 4 |
| 2026-09-01 | $-3.45 | $144,707 | 3 / 4 |
| 2026-09-02 | $-3.45 | $144,707 | 3 / 4 |
| 2026-09-03 | $-3.45 | $144,707 | 3 / 4 |
| 2026-09-04 | $-3.45 | $144,707 | 3 / 4 |
| 2026-09-05 | $-3.45 | $144,707 | 3 / 4 |
| 2026-09-06 | $-3.45 | $144,707 | 3 / 4 |
| 2026-09-07 | $-3.45 | $144,707 | 3 / 4 |
| 2026-09-08 | $-3.45 | $144,707 | 3 / 4 |
| 2026-09-09 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-10 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-11 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-12 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-13 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-14 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-15 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-16 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-17 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-18 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-19 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-20 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-21 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-22 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-23 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-24 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-25 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-26 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-27 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-28 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-29 | $-3.48 | $144,707 | 3 / 4 |
| 2026-09-30 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-01 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-02 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-03 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-04 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-05 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-06 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-07 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-08 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-09 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-10 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-11 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-12 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-13 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-14 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-15 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-16 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-17 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-18 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-19 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-20 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-21 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-22 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-23 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-24 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-25 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-26 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-27 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-28 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-29 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-30 | $-3.48 | $144,707 | 3 / 4 |
| 2026-10-31 | $-3.48 | $144,707 | 3 / 4 |
| 2026-11-01 | $-3.48 | $144,707 | 3 / 4 |
| 2026-11-02 | $-3.48 | $144,707 | 3 / 4 |
| 2026-11-03 | $-3.48 | $144,707 | 3 / 4 |
| 2026-11-04 | $-3.48 | $144,707 | 3 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.